News
ZBH
108.87
+2.55%
2.71
Zimmer Biomet Holdings (NYSE:ZBH) Is Due To Pay A Dividend Of US$0.24
The board of Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) has announced that it will pay a dividend of US$0.24 per share...
Simply Wall St. · 4d ago
Zimmer (ZBH) Down 5.6% Since Last Earnings Report: Can It Rebound?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/02 15:31
Are Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Mixed Financials Driving The Negative Sentiment?
With its stock down 4.8% over the past three months, it is easy to disregard Zimmer Biomet Holdings (NYSE:ZBH). We...
Simply Wall St. · 05/27 18:40
Zimmer Biomet cut to Hold at Needham on growth concerns
Needham downgraded Zimmer Biomet (NYSE:ZBH) to Hold from Buy, projecting Warsaw, Indiana-based maker of musculoskeletal reconstruction products to lag peers in terms of revenue and earnings growth. The firm projects
Seekingalpha · 05/27 17:13
Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2022
Upgrades
Benzinga · 05/27 15:36
5 Analysts Have This to Say About Zimmer Biomet Holdings
Within the last quarter, Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings:
Benzinga · 05/27 15:08
Needham Downgrades Zimmer Biomet Holdings to Hold From Buy, Removes $143 Price Target, Citing Market Share Loss, Inflationary Pressure, Normalizing Sector Growth
MT Newswires · 05/27 05:43
FDA Denies Approval For NeuroOne Medical's Evo sEEG Electrode For Extended Use
Benzinga · 05/17 16:06
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
Investors are optimistic about Zimmer Biomet's (ZBH) better-than-expected revenues and robust performance across several geographies.
Zacks · 05/17 16:01
Zimmer Biomet declares $0.24 dividend
Zimmer Biomet (NYSE:ZBH) declares $0.24/share quarterly dividend, in line with previous. Forward yield 0.83% Payable July 29; for shareholders of record June 27; ex-div June 24. See ZBH Dividend Scorecard,
Seekingalpha · 05/17 11:14
Citigroup Adjusts Price Target on Zimmer Biomet Holdings to $125 From $135, Maintains Neutral Rating
MT Newswires · 05/17 10:35
Zimmer Biomet Debuts First-of-its-Kind Artificial Intelligence Capabilities for Omni™ Suite Intelligent Operating Room
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today introduced the availability of new artificial intelligence¹ (AI) capabilities within Omni™ Suite, an intelligent operating room (OR) designed to optimize surgical w...
PR Newswire · 05/10 11:00
Akerna Announces Financial Results for First Quarter 2022
Software revenue up 71%, total revenue up 73% year-over-yearDENVER, May 09, 2022 (GLOBE NEWSWIRE) -- Akerna (Nasdaq: KERN), a leading enterprise software company and developer of one of the most comprehensive technology infrastructures, ecosystems, and com...
GlobeNewswire · 05/09 20:30
Are Investors Undervaluing Zimmer Biomet Holdings, Inc. (NYSE:ZBH) By 31%?
How far off is Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) from its intrinsic value? Using the most recent financial...
Simply Wall St. · 05/09 17:03
Akerna Corp. Reminds Stockholders of Upcoming Annual Meeting; Urges Stockholders to Vote FOR all Proposals
DENVER, May 09, 2022 (GLOBE NEWSWIRE) -- Akerna Corp. (Nasdaq: KERN), a leading enterprise software company and developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry,...
GlobeNewswire · 05/09 13:01
SVB Leerink Maintains Outperform Rating for Zimmer Biomet Holdings: Here's What You Need To Know
SVB Leerink has decided to maintain its Outperform rating of Zimmer Biomet Holdings (NYSE:ZBH) and raise its price target from $135.00 to $140.00. Shares of Zimmer Biomet Holdings are trading up 0.82% over the last 24 hours, at $121.67 per share.
Benzinga · 05/04 16:14
Analyst Ratings for Zimmer Biomet Holdings
Within the last quarter, Zimmer Biomet Holdings (NYSE:ZBH) has observed the following analyst ratings:
Benzinga · 05/04 13:20
--SVB Leerink Adjusts Price Target on Zimmer Biomet Holdings to $140 From $135, Keeps Outperform Rating
MT Newswires · 05/04 09:47
--RBC Raises Price Target on Zimmer Biomet Holdings to $128 From $125, Maintains Sector Perform Rating
MT Newswires · 05/04 08:05
--Stifel Adjusts Price Target on Zimmer Biomet Holdings to $140 From $130, Reiterates Buy Rating
MT Newswires · 05/04 05:30
More
Webull provides a variety of real-time ZBH stock news. You can receive the latest news about Zimmer Biomet through multiple platforms. This information may help you make smarter investment decisions.
About ZBH
Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas and Global Businesses, consisting principally of the United States and other North, Central and South American markets; Europe, Middle East and Africa (EMEA), consisting principally of France, Germany, Italy, Spain and the United Kingdom, and Asia Pacific, consisting primarily of Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong and Malaysia.